Molecular Basis of Alpha 1-antitrypsin Deficiency and Its Potential Therapy by Gene Transfer
Overview
Authors
Affiliations
The gene for alpha 1-antitrypsin, a serum anti-protease, has been cloned and sequenced. The underlying mutation in the PiZ allele has been identified as a G to A conversion giving rise to the substitution of glu by lys at position 342. Preparation of specific probes has allowed prenatal diagnosis. Recombinant retroviruses containing the normal human alpha 1-antitrypsin gene have been constructed and used to infect NIH3T3 cells. Analysis of DNA, RNA and protein indicate that successful incorporation of the alpha 1-antitrypsin was achieved and that the gene was capable of being expressed. The feasibility of genetic replacement therapy has been demonstrated and further experiments justified.
Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Approaches and Future Directions.
Mitchell E, Khan Z Curr Pathobiol Rep. 2018; 5(3):243-252.
PMID: 29399420 PMC: 5780543. DOI: 10.1007/s40139-017-0147-5.
Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene Therapy.
Wozniak J, Wandtke T, Kopinski P, Chorostowska-Wynimko J Hum Gene Ther. 2015; 26(11):709-18.
PMID: 26413996 PMC: 4651033. DOI: 10.1089/hum.2015.044.
Hidaka Y, Tarle S, Fujimori S, Kamatani N, Kelley W, Palella T J Clin Invest. 1988; 81(3):945-50.
PMID: 3343350 PMC: 442550. DOI: 10.1172/JCI113408.
Molecular biology and respiratory disease. 7. The alpha 1 antitrypsin gene and chronic lung disease.
Kalsheker N, Morgan K Thorax. 1990; 45(10):759-64.
PMID: 2247868 PMC: 462722. DOI: 10.1136/thx.45.10.759.